Search
Liquidia Corp
LQDAAdd to Watchlist
78.930USD
-0.390-0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
6.97BMarket Cap
315.43P/E TTM
More Details of Liquidia Corp Company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Liquidia Corp Info
Ticker SymbolLQDA
Company nameLiquidia Corp
IPO dateJul 26, 2018
CEOJeffs (Roger A)
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 26
Address419 Davis Drive
CityMORRISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27560
Phone19193284400
Websitehttps://www.liquidia.com/
Ticker SymbolLQDA
IPO dateJul 26, 2018
CEOJeffs (Roger A)
Company Executives of Liquidia Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-2.25%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
453.86K
+11.11%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
181.65K
+1.24%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
130.44K
-10.97%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
66.29K
-167.81%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
58.24K
+10.10%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
51.06K
-227.72%
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
26.24K
+22.42%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
21.24K
+27.69%
Dr. Stephen M. Bloch
Dr. Stephen M. Bloch
Independent Chairman of the board
Independent Chairman of the board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-2.25%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
453.86K
+11.11%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
181.65K
+1.24%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
130.44K
-10.97%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
66.29K
-167.81%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
58.24K
+10.10%
FAQs
Who are the top five shareholders of Liquidia Corp?
The top five shareholders of Liquidia Corp are: Dr. Roger A. Jeffs, Ph.D.
How many institutions hold shares of Liquidia Corp (LQDA)?
As of 2026Q1, 439 institutions hold shares of Liquidia Corp, with a combined market value of approximately 65.17M, accounting for 73.52% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6796421.00.